18F‐flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study

• Published in: Annals of neurology Vol. 82; no. 4; pp. 622 - 634
• Main Authors: Schonhaut, Daniel R., McMillan, Corey T., Spina, Salvatore, Dickerson, Bradford C., Siderowf, Andrew, Devous, Michael D., Tsai, Richard, Winer, Joseph, Russell, David S., Litvan, Irene, Roberson, Erik D., Seeley, William W., Grinberg, Lea T., Kramer, Joel H., Miller, Bruce L., Pressman, Peter, Nasrallah, Ilya, Baker, Suzanne L., Gomperts, Stephen N., Johnson, Keith A., Grossman, Murray, Jagust, William J., Boxer, Adam L., Rabinovici, Gil D.
• Format: Journal Article
• Language: English
• Published: Minneapolis Wiley Subscription Services, Inc 01.10.2017
• Subjects: Alzheimer's disease; Binding; Brain; Cerebellum; Criteria; Degeneration; Dentate nucleus; Disease control; Emissions control; Error correction; Globus pallidus; Group dynamics; Magnetic resonance imaging; Mesencephalon; Movement disorders; Neurodegeneration; Neurodegenerative diseases; Neurofibrillary tangles; Neuroimaging; Nuclei; Paralysis; Parkinson's disease; Pathology; Patients; Positron emission; Positron emission tomography; Progressive supranuclear palsy; Putamen; Qualitative analysis; Substantia grisea; Subthalamic nucleus; Tau protein; Tomography; β-Amyloid

Objective 18F‐flortaucipir (formerly 18F‐AV1451 or 18F‐T807) binds to neurofibrillary tangles in Alzheimer disease, but tissue studies assessing binding to tau aggregates in progressive supranuclear palsy (PSP) have yielded mixed results. We compared in vivo 18F‐flortaucipir uptake in patients meeti...